Dura forecasts Ceclor CD, Keftab sales of $100 mil. in 2000 following acquisition from Lilly.
DURA PREDICTS CECLOR CD, KEFTAB ANTIBIOTIC SALES OF $100 MIL. in the year 2000, the company said Aug. 22 announcing the acquisition of U.S. marketing rights to the two antibiotics from Lilly for approximately $100 mil. Under the marketing agreement, Lilly will manufacture Keftab and Ceclor CD, which gained FDA approval June 24. Dura expects to launch the twice-a-day Ceclor (cefaclor) this autumn and plans to promote Keftab (cephalexin) to physicians immediately. Keftab's current annual sales are about $15 mil., Dura said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth